Literature DB >> 31207027

Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH.

Aurelien Delluc1, Tzu-Fei Wang2, Eng-Soo Yap3, Cihan Ay4, Jordan Schaefer5, Marc Carrier1, Simon Noble6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31207027     DOI： 10.1111/jth.14478

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  12 in total

1.  DOACs for stroke prevention in patients with AF and cancer.

Authors:  Dipal Mehta; Daniel M Jones; Avirup Guha; Peter K MacCallum; Amitava Banerjee; Charlotte Manisty; Thomas Crake; Mark Westwood; Arjun K Ghosh
Journal:  Br J Cardiol       Date:  2020-12-02

2.  Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors.

Authors:  Tzu-Fei Wang; Anna E Clarke; Arif A Awan; Peter Tanuseputro; Marc Carrier; Manish M Sood
Journal:  JAMA Netw Open       Date:  2022-06-01

3.  Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.

Authors:  Esin Aysel Kandemir; Aygin Bayraktar-Ekincioglu; Saadettin Kilickap
Journal:  Support Care Cancer       Date:  2020-08-10       Impact factor: 3.603

Review 4.  Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation.

Authors:  Gianluca Botto; Pietro Ameri; Manuel Cappellari; Francesco Dentali; Nicola Ferri; Iris Parrini; Italo Porto; Alessandro Squizzato; Giuseppe Camporese
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

Review 5.  Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation.

Authors:  Anetta Undas; Leszek Drabik
Journal:  Anatol J Cardiol       Date:  2020-01       Impact factor: 1.596

Review 6.  Anticoagulation for atrial fibrillation in active cancer.

Authors:  Dimitrios Farmakis; Pavlos Papakotoulas; Eleni Angelopoulou; Theodoros Bischiniotis; George Giannakoulas; Panagiotis Kliridis; Dimitrios Richter; Ioannis Paraskevaidis
Journal:  Oncol Lett       Date:  2022-02-17       Impact factor: 2.967

Review 7.  Interactions between cardiology and oncology drugs in precision cardio-oncology.

Authors:  Sailaja Kamaraju; Meera Mohan; Svetlana Zaharova; Brianna Wallace; Joseph McGraw; James Lokken; John Tierney; Elizabeth Weil; Olubadewa Fatunde; Sherry-Ann Brown
Journal:  Clin Sci (Lond)       Date:  2021-06-11       Impact factor: 6.124

8.  Use of antithrombotics at the end of life: an in-depth chart review study.

Authors:  Bregje A A Huisman; Eric C T Geijteman; Jimmy J Arevalo; Marianne K Dees; Lia van Zuylen; Karolina M Szadek; Agnes van der Heide; Monique A H Steegers
Journal:  BMC Palliat Care       Date:  2021-07-16       Impact factor: 3.234

Review 9.  Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.

Authors:  Rupert Bauersachs; Alok A Khorana; Agnes Y Y Lee; Gerald Soff
Journal:  Res Pract Thromb Haemost       Date:  2020-04-04

10.  Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines.

Authors:  Joachim Alexandre; Jennifer Cautela; Stéphane Ederhy; Ghandi Laurent Damaj; Joe-Elie Salem; Fabrice Barlesi; Laure Farnault; Aude Charbonnier; Mariana Mirabel; Stéphane Champiat; Alain Cohen-Solal; Ariel Cohen; Charles Dolladille; Franck Thuny
Journal:  J Am Heart Assoc       Date:  2020-09-05       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.